In the competitive landscape of the 21st-century global economy, research and development (R&D) serves as the lifeblood of corporate growth, technological advancement, and national prosperity. Within the United States tax code, the treatment of R&D expenditures acts as a pivotal lever, influencing not only the magnitude of investment but also the geographic strategy of American multinational enterprises (MNEs).
As the U.S. government navigates the complexities of fiscal policy, the divergence between domestic and foreign R&D tax treatment has emerged as a central, yet contentious, issue. While domestic R&D enjoys the benefits of immediate expensing, foreign-based R&D faces mandatory 15-year amortization. This bifurcated system, intended by some as a tool for economic protectionism, may inadvertently be undermining the very innovation it seeks to foster.
The Mechanics of R&D Taxation: A Chronology of Policy Shifts
To understand the current environment, one must look at the recent evolution of Section 174 of the Internal Revenue Code. For decades, the U.S. tax system generally allowed for the immediate expensing of R&D costs, recognizing them as essential business inputs. However, the 2020s introduced a period of significant volatility.
In a move that drew widespread criticism from economic policy experts, the U.S. briefly mandated the amortization of all R&D, regardless of location. This policy shift created immediate liquidity pressures for firms heavily invested in innovation. Recognizing the stifling effect this had on the broader economy, the subsequent passage of the "One Big Beautiful Bill Act" (OBBBA) reversed course for domestic R&D, restoring the ability to expense these costs immediately.
Crucially, however, the OBBBA did not extend this reversal to foreign R&D. Under current law, domestic taxpayers may choose between immediate expensing or amortizing their domestic R&D over 60 months—a flexibility that allows firms to manage their tax liabilities in years where they may hold net operating losses. Conversely, foreign R&D remains tethered to Section 174, requiring mandatory capitalization and amortization over 15 years. This legal distinction represents a fundamental shift in the U.S. approach to globalized corporate operations.
The Economic Framework: Marginal Investment and the User Cost of Capital
The debate over expensing versus amortization is not merely a matter of accounting convenience; it is a question of capital allocation efficiency. As Robert Hall and Dale Jorgenson demonstrated in their seminal 1967 research, the timing of tax deductions exerts a profound influence on the "user cost of capital"—the hurdle rate a project must clear to be deemed viable.
When a firm considers an investment, it calculates the present value of future revenues against the costs of capital. Full expensing, by allowing the immediate recovery of costs, effectively reduces the tax burden on the marginal investment to zero. In this framework, the government essentially subsidizes the upfront cost, offsetting future taxes on the project’s gains. This creates a neutral tax environment that encourages firms to pursue every project that is economically sound.
In contrast, 15-year amortization artificially inflates the user cost of capital. By pushing the recovery of costs into the distant future, the tax code imposes a "tax penalty" on foreign R&D. Projects that would be profitable in a neutral tax environment are rendered unviable under the current U.S. regime. While this may seem like a strategic "onshoring" mechanism, economic theory suggests it serves as a barrier to efficient global resource allocation.
Complementarity: Why Global and Domestic R&D Are Not Zero-Sum
A common misconception among policymakers is that foreign R&D acts as a substitute for domestic investment—that every dollar spent in a foreign lab is a dollar taken away from a U.S. facility. However, empirical evidence from organizations like the Peterson Institute for International Economics (PIIE) and the Information Technology and Innovation Foundation (ITIF) suggests the opposite: global and domestic R&D are deeply complementary.
The Role of Market Adaptation
Foreign R&D is rarely an attempt to abandon the U.S. market. Instead, it is often a necessity for export-led growth. To sell products successfully in diverse global markets, firms must adapt their offerings to local languages, regulatory standards, climate requirements, and infrastructure. Pharmaceutical companies, for example, must conduct localized clinical trials to satisfy foreign health authorities. By funding these activities abroad, U.S. companies do not displace domestic jobs; they unlock global revenue streams that support the expansion of their primary U.S. research hubs.
Knowledge Networks and Scaling
The acquisition of foreign research teams is another vital component of modern innovation. When a U.S. firm acquires a foreign entity holding a specialized patent or software capability, it integrates that intellectual property into its broader corporate infrastructure. This frequently necessitates increased investment within the United States to scale the technology, manufacture the products, and manage global distribution. As noted by economists Gary Hufbauer and Theodore Moran, hindering the globalization of R&D operations often results in a "stifling" effect on the U.S. headquarters, as the firm loses its ability to integrate global competencies.
Implications for Global Competitiveness and M&A
The current tax regime places U.S. companies at a distinct disadvantage in the global market for mergers and acquisitions (M&A). When a U.S. firm bids on an R&D-intensive target, it must calculate its offer based on a 15-year amortization schedule for the target’s future R&D spending. Meanwhile, a foreign competitor—operating under more favorable tax laws in its home country—can expense those same costs immediately.
This disparity creates a structural "valuation gap." The U.S. firm’s after-tax valuation of the target is lower than that of its foreign rival, leading to lost bidding wars and a retreat from critical technological sectors. The Semiconductor Industry Association has repeatedly highlighted this issue, noting that such tax-induced disadvantages directly threaten the U.S. lead in emerging technologies like artificial intelligence, quantum computing, and advanced materials.
The Case for Neutrality
The path forward for U.S. tax policy requires a transition toward neutrality. By penalizing foreign R&D, the current system risks eroding the very base of American innovation. If U.S. firms are less competitive in the global market, they generate less taxable income, employ fewer people in high-value roles, and contribute less to the nation’s overall knowledge network.
Policymakers should prioritize:
- Harmonizing R&D Treatment: Moving toward a consistent tax treatment for R&D, regardless of the geographic location of the research, would reduce the tax-induced distortions that currently hamper investment decisions.
- Eliminating the "Onshoring" Bias: Recognizing that foreign R&D is a force-multiplier for domestic activity, rather than a competitor.
- Enhancing M&A Competitiveness: Leveling the playing field so that U.S. companies can compete fairly for innovative assets on the global stage.
Conclusion: Sustaining the American Innovation Engine
The treatment of R&D expenditures is one of the most critical levers in the U.S. tax code. While the desire to incentivize domestic activity is understandable, the current divergence in the tax treatment of foreign and domestic R&D is an outdated approach that ignores the realities of the modern, interconnected economy.
True innovation thrives in an environment of efficiency and global connectivity. By shifting away from a protectionist tax framework and toward one that treats R&D as a singular, vital, and global endeavor, the United States can ensure that its companies remain at the forefront of the next generation of technological breakthroughs. The cost of inaction is not merely a budgetary concern—it is a long-term risk to the competitiveness and vitality of the American economy.
